| 2024-10-06 | Hypertension - HTN guidelines | 0:00 | 2 | |
|
| 2024-10-06 | Multiple myeloma - Diagnostic criteria | 0:00 | 11 | |
|
| 2024-10-06 | Hypokalemia - Causes | 0:00 | 3 | |
|
| 2024-10-05 | Myasthenia gravis - Hallmark signs | 0:00 | 1 | |
|
| 2024-10-05 | Calcium receptor agonist | 0:00 | 11 | |
|
| 2024-10-05 | Tension pneumothorax - Emergency management | 0:00 | 13 | |
|
| 2024-10-05 | Pulmonary hypertension - Common causes | 0:00 | 11 | |
|
| 2024-10-05 | Morphine / Opiods uses | 0:00 | 1 | |
|
| 2024-10-05 | Oxytocin receptor antagonist | 0:00 | 2 | |
|
| 2024-10-05 | Somatostatin analogs | 0:00 | 13 | |
|
| 2024-10-05 | Vasopressin receptor antagonist | 0:00 | 2 | |
|
| 2024-10-05 | Vasopressin receptor agonists | 0:00 | 1 | |
|
| 2024-10-05 | IGF 1 agonist | 0:00 | 4 | |
|
| 2024-10-05 | Peptic ulcer disease - Common causes | 0:00 | 4 | |
|
| 2024-10-05 | Sjogren syndrome - Key features | 0:00 | 5 | |
|
| 2024-10-05 | Gonadotropins | 0:00 | 10 | |
|
| 2024-10-05 | Marfans syndrome - Key features | 0:00 | 13 | |
|
| 2024-10-05 | Morphine central pharmacological effects | 0:00 | 1 | |
|
| 2024-10-05 | Addisons disease - signs and management | 0:00 | 4 | |
|
| 2024-10-05 | Lupus nephritis - Diagnostic approach | 0:00 | 4 | |
|
| 2024-10-05 | Growth hormone | 0:00 | 3 | |
|
| 2024-10-05 | Morphine peripheral pharmacological effects | 0:00 | 1 | |
|
| 2024-10-04 | Bromocriptine | 0:00 | 1 | |
|
| 2024-10-04 | Gonadotropin luteinizing hormone | 0:00 | 1 | |
|
| 2024-10-04 | Drugs acting on male hormones | 0:00 | 23 | |
|
| 2024-10-04 | Pernicious anemia - Key findings | 0:00 | 0 | |
|
| 2024-10-04 | Gonadotropin releasing hormone - Gnrh analogs | 0:00 | 0 | |
|
| 2024-10-04 | Glasgow coma scale GCS | 0:00 | 7 | |
|
| 2024-10-04 | Gullian barre syndrome - Classic signs | 0:00 | 9 | |
|
| 2024-10-04 | Hypoglycaemia drugs - overcome insulin resistance part 2 | 0:00 | 37 | |
|
| 2024-10-04 | Cushing syndrome - Clinical features | 0:00 | 2 | |
|
| 2024-10-04 | Rank ligand inhibitor | 0:00 | 1 | |
|
| 2024-10-04 | Corticosteroids - Diagnostic uses | 0:00 | 2 | |
|
| 2024-10-04 | Hypoglycaemia drugs - Enhance insulin secretion | 0:00 | 20 | |
|
| 2024-10-04 | Eclampsia - Management protocol | 0:00 | 0 | |
|
| 2024-10-04 | Pulmonary embolism - Clinical presentation | 0:00 | 0 | |
|
| 2024-10-04 | Oxytocin | 0:00 | 1 | |
|
| 2024-10-04 | Diabetic ketoacidosis - Essential criteria | 0:00 | 5 | |
|
| 2024-10-04 | Hypertension - JNC 8 Guidelines | 0:00 | 6 | |
|
| 2024-10-04 | Coarctation of aorta - Presentation | 0:00 | 2 | |
|
| 2024-10-04 | Hepatitis B - Serology interpretation | 0:00 | 0 | |
|
| 2024-10-04 | Hypoglycaemia drugs - overcome insulin resistance part 1 | 0:00 | 10 | |
|
| 2024-10-04 | Gonadotropin releasing hormone - Gnrh receptor antagonist | 0:00 | 0 | |
|
| 2024-10-04 | SERM - Selective estrogen receptor modulators | 0:00 | 6 | |
|
| 2024-10-04 | Anaphylaxis - Management | 0:00 | 0 | |
|
| 2024-10-04 | Bell’s palsy - Key characteristics | 0:00 | 4 | |
|
| 2024-10-03 | Glucocorticoids - Adverse effects | 0:00 | 0 | |
|
| 2024-10-02 | Antifungal drugs - Part 3 | 0:00 | 0 | |
|
| 2024-10-02 | Antimalarial drugs - Plasmodium falciparum | 0:00 | 0 | |
|
| 2024-10-02 | Antiprotozoal drugs | 0:00 | 0 | |
|
| 2024-10-02 | Urinary tract infection - UTI treatment | 0:00 | 0 | |
|
| 2024-10-02 | Penicillin - Classification | 0:00 | 0 | |
|
| 2024-10-02 | Antifungal drugs - part 2 | 0:00 | 0 | |
|
| 2024-10-02 | Antimicrobials in renal failure | 0:00 | 0 | |
|
| 2024-10-02 | Antimicrobials in Liver disease | 0:00 | 1 | |
|
| 2024-10-02 | Anti fungal drugs - Part 1 | 0:00 | 1 | |
|
| 2024-10-02 | Anti malarial drugs - Plasmodium vivax | 0:00 | 1 | |
|
| 2024-10-02 | Antiviral drugs | 0:00 | 4 | |
|
| 2024-10-02 | HIV - Drugs | 0:00 | 2 | |
|
| 2024-10-01 | Status asthmaticus | 0:00 | 4 | |
|
| 2024-10-01 | H Pylori - Eradication | 0:00 | 7 | |
|
| 2024-09-30 | Constipation - Drugs | 0:00 | 0 | |
|
| 2024-09-30 | Antiprotozoal drugs | 0:00 | 0 | |
|
| 2024-09-29 | Antihelminthic drugs | 0:00 | 0 | |
|
| 2024-09-29 | Leprosy and treatment | 0:00 | 0 | |
|
| 2024-09-29 | Mycobacterum avian complex | 0:00 | 1 | |
|
| 2024-09-29 | Dyslipidemia drugs - Part 2 | 0:00 | 0 | |
|
| 2024-09-29 | Heparin | 0:00 | 0 | |
|
| 2024-09-29 | Warfarin | 0:00 | 4 | |
|
| 2024-09-29 | Warfarin overdose | 0:00 | 2 | |
|
| 2024-09-29 | Diarrhea - Drugs | 0:00 | 2 | |
|
| 2024-09-29 | Thrombolytics - Fibrinolytics | 0:00 | 0 | |
|
| 2024-09-29 | Antifibrinolytics | 0:00 | 0 | |
|
| 2024-09-29 | Dyslipidemia drugs - part 1 | 0:00 | 0 | |
|
| 2024-09-29 | Prevention of venothromboembolism | 0:00 | 6 | |
|
| 2024-09-29 | Monoclonal antibodies | 0:00 | 0 | |
|
| 2024-09-29 | Platelet inhibitors and adverse effects | 0:00 | 0 | |
|
| 2024-09-29 | Platinum compounds | 0:00 | 1 | |
|
| 2024-09-28 | Pregnancy - Unsafe drugs part 2 | 0:00 | 1 | |
|
| 2024-09-28 | Anti cancer drugs - Part 1 | 0:00 | 4 | |
|
| 2024-09-28 | Anticancer drugs - adverse effects part 2 | 0:00 | 1 | |
|
| 2024-09-28 | Pregnancy - Safe drugs | 0:00 | 4 | |
|
| 2024-09-28 | Immunomodulators part 1 | 0:00 | 1 | |
|
| 2024-09-28 | Pregnancy - Unsafe drugs | 0:00 | 2 | |
|
| 2024-09-28 | Pregnancy drug categories | 0:00 | 4 | |
|
| 2024-09-28 | Local anaesthetics | 0:00 | 7 | |
|
| 2024-09-28 | Chelating agents - Part 1 | 0:00 | 0 | |
|
| 2024-09-28 | Immunomodulators - Part 2 | 0:00 | 1 | |
|
| 2024-09-28 | Chelating agents - Part 2 | 0:00 | 0 | |
|
| 2024-09-28 | Pregnancy - Safe drugs part 2 | 0:00 | 1 | |
|
| 2024-09-27 | Central Skeletal muscle relaxants | 0:00 | 0 | |
|
| 2024-09-26 | Cell to cell anchoring junctions | 0:00 | 0 | |
|
| 2024-09-26 | Gap junction | 0:00 | 0 | |
|
| 2024-09-26 | Cell to basal lamina anchoring junctions | 0:00 | 0 | |
|
| 2024-09-26 | Gain of control system | 0:00 | 1 | |
|
| 2024-09-26 | Nernst equation | 0:00 | 1 | |
|
| 2024-09-26 | Doonan effect | 0:00 | 1 | |
|
| 2024-09-25 | Golgi complex | 0:00 | 3 | |
|
| 2024-09-25 | Vascular transport - Exocytosis and endocytosis | 0:00 | 2 | |
|
| 2024-09-25 | Carrier mediated transport - Features | 0:00 | 2 | |
|
